Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Trial shows promise for facial tumour cure
Lead author Dr Cesar Tovar said the findings confirm it is possible to trigger the devil’s immune system to recognise and destroy DFTD tumours.
Immunotherapy shrank tumours in Tasmanian devils

Scientists say they have had a ‘eureka’ moment in using immunotherapy to cure Tasmanian devils of the deadly devil facial tumour disease (DFTD).

Led by the University of Tasmania, an international research team used immunotherapy on devils with golf-ball-sized tumours and observed the tumours shrinking and disappearing over a period of three months.

“This is almost a eureka moment for us because it’s the first time we can say for sure that it was the immunotherapy that was making the tumour shrink,” said Professor Greg Woods, who led the team at the university’s Menzies Institute for Medical Research.

Lead author Dr Cesar Tovar added that the findings confirm it is possible to trigger the devil’s immune system to recognise and destroy DFTD tumours.

“Our research shows that a DFTD vaccine is feasible. We are focusing our efforts on developing strategies to improve the devils’ response to immunisation.”

The breakthrough is the next step on from research published in 2015, which revealed the devil’s immune system was capable of mounting an immune response to DFTD.

“This is an important step along the way to developing a vaccine to protect against DFTD and potentially to cure devils of established DFTD,” Prof Woods added.

Become a member or log in to add this story to your CPD history

Webinar to explore AMR in vet dentistry

News Story 1
 The WSAVA has invited veterinary professionals to a webinar on responsible antibiotic usage in dentistry.

On 19 November 2025, at 1am, Dr J Scott Weese and Dr Brooke Niemiec will share the latest advice for antimicrobial use. They will present research on oral bacterology, and explain how attendees can choose appropriate antibiotics.

The session will cover pre-, intra- and post-operative guidelines, with recommendations for various pathologies.

The webinar is designed to support veterinary professionals to make informed decisions and tackle antimicrobial resistance.

Attendees can register here

Click here for more...
News Shorts
Bluetongue reaches Wales for first time in 2025

The Animal and Plant Health Agency (APHA) has revealed that bluetongue has been confirmed in Wales for the first time in 2025.

In their latest statistics, APHA records a total of 109 cases of BTV-3 or BTV-8 in Great Britain in the 2025-2026 vector season.

The total number of BTV-3 cases in Great Britain this season is 107. This includes 103 cases within the England restricted zone and four cases in Wales.

There has also been two cases of BTV-8, which were both in Cornwall.

As a result of the cases in Wales, a Temporary Control Zone (TCZ) is enforced in Monmouthshire. Animals can move freely under general license within the England Restricted Zone, however animals with suspected bluetongue must stay on their holding.

All premises testing positive for blue tongue can be viewed on this map.